Genmab Signs US$1.1 B Daratumumab Licence Agreement with Janssen Biotech
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 5 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1801 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Johnson & Johnson’s Janssen Biotech has licensed global development and commercialisation rights to Genmab’s human CD38 monoclonal antibody daratumumab in a deal potentially worth US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS